Roivant Sciences (ROIV) Free Cash Flow (2020 - 2025)
Roivant Sciences (ROIV) posted Free Cash Flow of -$593.5 million for Q4 2025, down 206.69% on a QoQ basis from -$193.5 million in Q3 2025, and up 11.51% year-over-year from -$532.2 million in Q4 2024.
Roivant Sciences (ROIV) Free Cash Flow (2020 - 2025) Analysis & Trends
Roivant Sciences' Free Cash Flow history runs 6 years deep, the most recent figure standing at -$593.5 million for Q4 2025.
- Quarterly Free Cash Flow rose 11.51% year-over-year to -$593.5 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$995.4 million (up 12.09% YoY) and the FY2026 annual result came in at -$757.8 million, up 10.22% from the prior year.
- Free Cash Flow was -$593.5 million for Q4 2025 at Roivant Sciences, down from -$193.5 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$123.4 million in Q3 2021 and bottomed at -$675.4 million in Q4 2022.
- A 5-year average of -$344.6 million and a median of -$250.3 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2021 — Free Cash Flow sank 199.26% — and 2025, when it climbed 27.74%.
- Roivant Sciences' Free Cash Flow stood at -$541.4 million in 2021, then declined by 24.74% to -$675.4 million in 2022, then gained by 2.6% to -$657.8 million in 2023, then decreased by 1.95% to -$670.7 million in 2024, then gained by 11.51% to -$593.5 million in 2025.
- Business Quant data shows ROIV's Free Cash Flow at -$593.5 million in Q4 2025, -$193.5 million in Q3 2025, and -$208.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Roivant Sciences | 24.35 Bn | 25.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -593.48 Mn |
| Dec 31, 2025 | -593.48 Mn |
| Sep 30, 2025 | -193.51 Mn |
| Sep 30, 2025 | -193.51 Mn |
| Jun 30, 2025 | -208.42 Mn |
| Jun 30, 2025 | -208.42 Mn |
| Dec 31, 2024 | -670.67 Mn |
| Dec 31, 2024 | -670.67 Mn |
| Sep 30, 2024 | -267.80 Mn |
| Sep 30, 2024 | -267.80 Mn |
| Jun 30, 2024 | -193.79 Mn |
| Jun 30, 2024 | -193.79 Mn |
| Dec 31, 2023 | -657.84 Mn |
| Dec 31, 2023 | -657.84 Mn |
| Sep 30, 2023 | -196.70 Mn |
| Sep 30, 2023 | -196.70 Mn |
| Jun 30, 2023 | -250.34 Mn |
| Jun 30, 2023 | -250.34 Mn |
| Dec 31, 2022 | -675.37 Mn |
| Dec 31, 2022 | -675.37 Mn |